 These include adriamycin and other anthracyclines, bleomycin, and cisplatin.These agents may show specific toxicity towards cancer cells because of the low level of antioxidant defenses found in tumors.Recent research demonstrates that redox dysregulation originating from metabolic alterations and dependence on mitogenic and survival signaling through reactive oxygen species represents a specific vulnerability of malignant cells that can be selectively targeted by pro-oxidant non-genotoxic redox chemotherapeutics.